Author:
Gholamian Marsa,Yazdi Mehran,Faghihi Reza
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Birckhead BJ, Fossum CC, Deufel CL, Furutani KM, Merrell KW, Schueler BA, Mynderse LA, Choo R, Davis BJ. Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by day 0 fluoroscopy and 4-month postimplant pelvic x-ray. Am Brachytherapy Soc. 2016;15(6):714–21.
2. Bloch BN, Lenkinski RE, Helbich TH, et al. Prostate postbrachytherapy seed distribution: comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: initial experience. Int J Radiat Oncol Biol Phys. 2007;69:70–8.
3. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, et al. Brachytherapy for patients with prostate cancer: american society of clinical oncology/cancer care Ontario joint guideline update. J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2016.72.0466.
4. Crehange G, Roach M, Martin E, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother. 2014;18(524):e534.
5. De Brabandere M, Hoskin P, Haustermans K, Van Den Heuvel F, Siebert FA. Prostate post-implant dosimetry: Interobserver variability in seed localisation, contouring and fusion. Radiother Oncol. 2012;104:192–8.